Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 196

1.

Colorectal cancer prevention: Immune modulation taking the stage.

Fletcher R, Wang YJ, Schoen RE, Finn OJ, Yu J, Zhang L.

Biochim Biophys Acta. 2018 Apr;1869(2):138-148. doi: 10.1016/j.bbcan.2017.12.002. Epub 2018 Jan 31. Review.

PMID:
29391185
2.

A Believer's Overview of Cancer Immunosurveillance and Immunotherapy.

Finn OJ.

J Immunol. 2018 Jan 15;200(2):385-391. doi: 10.4049/jimmunol.1701302. Review.

PMID:
29311379
3.

mSA2 affinity-enhanced biotin-binding CAR T cells for universal tumor targeting.

Lohmueller JJ, Ham JD, Kvorjak M, Finn OJ.

Oncoimmunology. 2017 Oct 26;7(1):e1368604. doi: 10.1080/2162402X.2017.1368604. eCollection 2017.

4.

Abnormally glycosylated MUC1 establishes a positive feedback circuit of inflammatory cytokines, mediated by NF-κB p65 and EzH2, in colitis-associated cancer.

Cascio S, Faylo JL, Sciurba JC, Xue J, Ranganathan S, Lohmueller JJ, Beatty PL, Finn OJ.

Oncotarget. 2017 Oct 27;8(62):105284-105298. doi: 10.18632/oncotarget.22168. eCollection 2017 Dec 1.

5.

The dawn of vaccines for cancer prevention.

Finn OJ.

Nat Rev Immunol. 2018 Mar;18(3):183-194. doi: 10.1038/nri.2017.140. Epub 2017 Dec 27. Review.

PMID:
29279613
6.

Is It Possible to Develop Cancer Vaccines to Neoantigens, What Are the Major Challenges, and How Can These Be Overcome? Neoantigens: Nothing New in Spite of the Name.

Finn OJ, Rammensee HG.

Cold Spring Harb Perspect Biol. 2017 Dec 18. pii: a028829. doi: 10.1101/cshperspect.a028829. [Epub ahead of print]

PMID:
29254980
7.

Human Tumor Antigens Yesterday, Today, and Tomorrow.

Finn OJ.

Cancer Immunol Res. 2017 May;5(5):347-354. doi: 10.1158/2326-6066.CIR-17-0112. Review.

8.

Precancer Atlas to Drive Precision Prevention Trials.

Spira A, Yurgelun MB, Alexandrov L, Rao A, Bejar R, Polyak K, Giannakis M, Shilatifard A, Finn OJ, Dhodapkar M, Kay NE, Braggio E, Vilar E, Mazzilli SA, Rebbeck TR, Garber JE, Velculescu VE, Disis ML, Wallace DC, Lippman SM.

Cancer Res. 2017 Apr 1;77(7):1510-1541. doi: 10.1158/0008-5472.CAN-16-2346.

9.

Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines.

Lohmueller J, Finn OJ.

Pharmacol Ther. 2017 Oct;178:31-47. doi: 10.1016/j.pharmthera.2017.03.008. Epub 2017 Mar 16. Review.

PMID:
28322974
11.

Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer.

Scheid E, Major P, Bergeron A, Finn OJ, Salter RD, Eady R, Yassine-Diab B, Favre D, Peretz Y, Landry C, Hotte S, Mukherjee SD, Dekaban GA, Fink C, Foster PJ, Gaudet J, Gariepy J, Sekaly RP, Lacombe L, Fradet Y, Foley R.

Cancer Immunol Res. 2016 Oct;4(10):881-892. Epub 2016 Sep 7.

12.

Antibodies elicited by the first non-viral prophylactic cancer vaccine show tumor-specificity and immunotherapeutic potential.

Lohmueller JJ, Sato S, Popova L, Chu IM, Tucker MA, Barberena R, Innocenti GM, Cudic M, Ham JD, Cheung WC, Polakiewicz RD, Finn OJ.

Sci Rep. 2016 Aug 22;6:31740. doi: 10.1038/srep31740.

13.

Immunobiology and immunosurveillance in patients with intraductal papillary mucinous neoplasms (IPMNs), premalignant precursors of pancreatic adenocarcinomas.

Beatty PL, van der Geest R, Hashash JG, Kimura T, Gutkin D, Brand RE, Finn OJ.

Cancer Immunol Immunother. 2016 Jul;65(7):771-8. doi: 10.1007/s00262-016-1838-1. Epub 2016 Apr 22.

PMID:
27106024
14.

Cancer immunoprevention.

Finn OJ, Beatty PL.

Curr Opin Immunol. 2016 Apr;39:52-8. doi: 10.1016/j.coi.2016.01.002. Epub 2016 Jan 19. Review.

15.

Anti-MUC1 Antibody in Nipple Aspirate Fluids Correlates with Tumor Aggressiveness in Breast Cancer: A Feasibility Study.

Menekse E, McKolanis J, Finn OJ, McAuliffe PF, Johnson R, Soran A.

Dis Markers. 2015;2015:179689. doi: 10.1155/2015/179689. Epub 2015 Nov 29.

16.

The FDA guidance on therapeutic cancer vaccines: the need for revision to include preventive cancer vaccines or for a new guidance dedicated to them.

Finn OJ, Khleif SN, Herberman RB.

Cancer Prev Res (Phila). 2015 Nov;8(11):1011-6. doi: 10.1158/1940-6207.CAPR-15-0234. Epub 2015 Sep 9.

17.

Complex of MUC1, CIN85 and Cbl in Colon Cancer Progression and Metastasis.

Cascio S, Finn OJ.

Cancers (Basel). 2015 Feb 10;7(1):342-52. doi: 10.3390/cancers7010342.

18.

Vaccines for cancer prevention: a practical and feasible approach to the cancer epidemic.

Finn OJ.

Cancer Immunol Res. 2014 Aug;2(8):708-13. doi: 10.1158/2326-6066.CIR-14-0110. Review.

19.

Influenza virus infection elicits protective antibodies and T cells specific for host cell antigens also expressed as tumor-associated antigens: a new view of cancer immunosurveillance.

Iheagwara UK, Beatty PL, Van PT, Ross TM, Minden JS, Finn OJ.

Cancer Immunol Res. 2014 Mar;2(3):263-73. doi: 10.1158/2326-6066.CIR-13-0125. Epub 2013 Dec 5.

20.

Global Inhibition of DC Priming Capacity in the Spleen of Self-Antigen Vaccinated Mice Requires IL-10.

Marvel DM, Finn OJ.

Front Immunol. 2014 Feb 17;5:59. doi: 10.3389/fimmu.2014.00059. eCollection 2014.

21.

Novel mechanisms underlying the immediate and transient global tolerization of splenic dendritic cells after vaccination with a self-antigen.

Farkas AM, Finn OJ.

J Immunol. 2014 Jan 15;192(2):658-65. doi: 10.4049/jimmunol.1301904. Epub 2013 Dec 11.

22.

Generation and immunosuppressive functions of p53-induced human adaptive regulatory T cells.

Mandapathil M, Visus C, Finn OJ, Lang S, Whiteside TL.

Oncoimmunology. 2013 Jul 1;2(7):e25514. Epub 2013 Jul 3.

23.
25.

Incidence rate of breast cancer in young women.

Cramer DW, Finn OJ.

JAMA. 2013 Jun 19;309(23):2434-5. doi: 10.1001/jama.2013.6450. No abstract available.

PMID:
23780450
26.

Introduction to The Renaissance of Cancer Immunotherapy.

Finn OJ, Schuler G.

Ann N Y Acad Sci. 2013 May;1284:v-vii. doi: 10.1111/nyas.12153. No abstract available.

PMID:
23651200
27.

Preventing cancer by targeting abnormally expressed self-antigens: MUC1 vaccines for prevention of epithelial adenocarcinomas.

Beatty PL, Finn OJ.

Ann N Y Acad Sci. 2013 May;1284:52-6. doi: 10.1111/nyas.12108.

PMID:
23651193
28.
29.

MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study.

Kimura T, McKolanis JR, Dzubinski LA, Islam K, Potter DM, Salazar AM, Schoen RE, Finn OJ.

Cancer Prev Res (Phila). 2013 Jan;6(1):18-26. doi: 10.1158/1940-6207.CAPR-12-0275. Epub 2012 Dec 17.

30.

Host response in tumor diagnosis and prognosis: importance of immunologists and pathologists alliance.

Finn OJ.

Exp Mol Pathol. 2012 Dec;93(3):315-8. doi: 10.1016/j.yexmp.2012.10.013. Epub 2012 Oct 23. Review.

31.

MUC1 immunotherapy is here to stay.

Kimura T, Finn OJ.

Expert Opin Biol Ther. 2013 Jan;13(1):35-49. doi: 10.1517/14712598.2012.725719. Epub 2012 Sep 24. Review.

PMID:
22998452
32.

AACR Cancer Progress Report 2012.

Cantley LC, Dalton WS, DuBois RN, Finn OJ, Futreal PA, Golub TR, Hait WN, Lozano G, Maris JM, Nelson WG, Sawyers CL, Schreiber SL, Spitz MR, Steeg PS.

Clin Cancer Res. 2012 Nov 1;18(21 Suppl):S1-100. doi: 10.1158/1078-0432.CCR-12-2891. Epub 2012 Sep 11. No abstract available.

33.

Human mucin MUC1 RNA undergoes different types of alternative splicing resulting in multiple isoforms.

Zhang L, Vlad A, Milcarek C, Finn OJ.

Cancer Immunol Immunother. 2013 Mar;62(3):423-35. doi: 10.1007/s00262-012-1325-2. Epub 2012 Sep 2.

34.

Immuno-oncology: understanding the function and dysfunction of the immune system in cancer.

Finn OJ.

Ann Oncol. 2012 Sep;23 Suppl 8:viii6-9. doi: 10.1093/annonc/mds256. Review.

35.
36.

Preventive immunization of aged and juvenile non-human primates to β-amyloid.

Kofler J, Lopresti B, Janssen C, Trichel AM, Masliah E, Finn OJ, Salter RD, Murdoch GH, Mathis CA, Wiley CA.

J Neuroinflammation. 2012 May 3;9:84.

38.

Cyclin B1 expression and p53 status in squamous cell carcinomas of the head and neck.

Hoffmann TK, Trellakis S, Okulicz K, Schuler P, Greve J, Arnolds J, Bergmann C, Bas M, Lang S, Lehnerdt G, Brandau S, Mattheis S, Scheckenbach K, Finn OJ, Whiteside TL, Sonkoly E.

Anticancer Res. 2011 Oct;31(10):3151-7.

39.

IL-33 synergizes with TCR and IL-12 signaling to promote the effector function of CD8+ T cells.

Yang Q, Li G, Zhu Y, Liu L, Chen E, Turnquist H, Zhang X, Finn OJ, Chen X, Lu B.

Eur J Immunol. 2011 Nov;41(11):3351-60. doi: 10.1002/eji.201141629. Epub 2011 Oct 13.

40.

Importance of MUC1 and spontaneous mouse tumor models for understanding the immunobiology of human adenocarcinomas.

Finn OJ, Gantt KR, Lepisto AJ, Pejawar-Gaddy S, Xue J, Beatty PL.

Immunol Res. 2011 Aug;50(2-3):261-8. doi: 10.1007/s12026-011-8214-1. Review.

PMID:
21717081
41.

Preface: Happy 10th anniversary!

Finn OJ.

Immunol Res. 2011 Aug;50(2-3):103-4. doi: 10.1007/s12026-011-8233-y. No abstract available.

PMID:
21717062
42.

Cancer immunology.

Melief CJ, Finn OJ.

Curr Opin Immunol. 2011 Apr;23(2):234-6. doi: 10.1016/j.coi.2011.01.003. Epub 2011 Feb 1. No abstract available.

PMID:
21292460
43.

Epidemiologic perspective on immune-surveillance in cancer.

Cramer DW, Finn OJ.

Curr Opin Immunol. 2011 Apr;23(2):265-71. doi: 10.1016/j.coi.2011.01.002. Epub 2011 Feb 1. Review.

44.

Generation of a tumor vaccine candidate based on conjugation of a MUC1 peptide to polyionic papillomavirus virus-like particles.

Pejawar-Gaddy S, Rajawat Y, Hilioti Z, Xue J, Gaddy DF, Finn OJ, Viscidi RP, Bossis I.

Cancer Immunol Immunother. 2010 Nov;59(11):1685-96. doi: 10.1007/s00262-010-0895-0. Epub 2010 Jul 21.

45.

Tumor antigen epitopes interpreted by the immune system as self or abnormal-self differentially affect cancer vaccine responses.

Ryan SO, Turner MS, Gariépy J, Finn OJ.

Cancer Res. 2010 Jul 15;70(14):5788-96. doi: 10.1158/0008-5472.CAN-09-4519. Epub 2010 Jun 29.

46.

Mumps and ovarian cancer: modern interpretation of an historic association.

Cramer DW, Vitonis AF, Pinheiro SP, McKolanis JR, Fichorova RN, Brown KE, Hatchette TF, Finn OJ.

Cancer Causes Control. 2010 Aug;21(8):1193-201. doi: 10.1007/s10552-010-9546-1. Epub 2010 Jun 18.

47.

Anti-MUC1 antibodies and ovarian cancer risk: prospective data from the Nurses' Health Studies.

Pinheiro SP, Hankinson SE, Tworoger SS, Rosner BA, McKolanis JR, Finn OJ, Cramer DW.

Cancer Epidemiol Biomarkers Prev. 2010 Jun;19(6):1595-601. doi: 10.1158/1055-9965.EPI-10-0068. Epub 2010 May 25.

48.

Vaccines based on abnormal self-antigens as tumor-associated antigens: immune regulation.

Farkas AM, Finn OJ.

Semin Immunol. 2010 Jun;22(3):125-31. doi: 10.1016/j.smim.2010.03.003. Epub 2010 Apr 18. Review.

PMID:
20403708
49.

Vaccine against MUC1 antigen expressed in inflammatory bowel disease and cancer lessens colonic inflammation and prevents progression to colitis-associated colon cancer.

Beatty PL, Narayanan S, Gariépy J, Ranganathan S, Finn OJ.

Cancer Prev Res (Phila). 2010 Apr;3(4):438-46. doi: 10.1158/1940-6207.CAPR-09-0194. Epub 2010 Mar 23.

50.

Cancer vaccines: emphasis on pediatric cancers.

Guinipero T, Finn OJ.

Curr Pharm Des. 2010 Jan;16(3):292-9. Review.

PMID:
20109138

Supplemental Content

Support Center